A MULTI-CENTRED OPEN TRIAL OF “DR MICHAELS®” (ALSO BRANDED AS SORATINEX®) TOPICAL PRODUCT FAMILY IN PSORIASIS


1Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany; 2nd Medical Faculty, Charles University, Bulovka Hospital; 3Institute of Clinical and Experimental Medicine, Prague, Czech Republic; 4Department of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy; 5Dermatological Department University of Pisa, Pisa, Italy; 6“Onkoderma”- Polyclinic for dermatology and dermatologic surgery, Sofia, Bulgaria; 7Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria; 8Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria; 9Psoriasis & Skin Clinic, Melbourne, Australia; 10PRO SANUM Ltd., Sanatorium of Prof. Novotný, Štěpánská Prague I, Czech Republic; 11University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India; 12Department “Medicinal Information and Non-interventional studies”, Bulgarian Drug Agency, Sofia, Bulgaria; 13Department of Dermatology & Cutaneous Surgery, Department of Psychiatry & Behavioral Sciences, Institute for Bioethics & Health Policy, University of Miami, Miller School of Medicine - Miami, FL, USA; 14Centro Studi per la Ricerca Multidisciplinare e Rigenerativa. Università Degli Studi “G. Marconi”, Rome, Italy; 15Chair of Dermatology, University of Rome “G. Marconi” Rome, Italy

Psoriasis is a chronic, recurring skin disease affecting 2–4% of the population. Genetic predisposition and precipitating factors play a role in its etiology. The disease can occur in any age or gender group. The most frequently affected areas of the body include scalp, extensor surfaces of the extremities, skin folds and nails. While a number of therapies exist for the treatment of psoriasis with a total resolution of the skin, achieving remission in a high percentage of sufferers, a treatment that results in the maintenance of remission and is free of side effects is still a desirable goal. The aim of the study was to investigate the efficacy and tolerability of Dr Michaels® (Soratinex®) topical product family in psoriasis, in terms of decreasing parakeratosis, inflammation, infiltration and involved area. Seven-hundred-and-twenty-two subjects, mean age 42.3 years (range: 18-68 years) with mild to moderately severe psoriasis, with no other current anti-psoriatic therapy, consisting of 382 males and 340 females, above 18 years of age were included and the observations were subjected to statistical analysis. Triphasic application of Dr Michaels® (Soratinex®) products was employed for 8 weeks, using Cleansing Gel, Scalp & Body Ointment and Skin Conditioner. The treatment proved to be ineffective for 22 patients (3.1%) out of 722. 84 patients (11.6%) had moderate improvement with 26-50% of cleared skin lesions; 102 patients (14.1%) had good improvement with 51-75% of cleared skin lesions; 484 patients (67.0%) experienced outstanding improvement with 76-100% of the cleared skin lesions with 52% of them achieving total resolution. Twelve patients worsened and discontinued treatment; 18 patients discontinued because of non-compliance; 33 patients developed folliculitis as a side effect. Based on the results of this study, the Dr Michaels® (Soratinex®) product family can be successfully applied in mild to moderately severe psoriasis when considering the exclusion criteria.

0393-974X (2016)